Unit

UNIT 13B.5 In Vitro Anti-Hepatitis C Virus (HCV) Resistance Selection and Characterization

  1. Hongmei Mo

Published Online: 1 JUN 2011

DOI: 10.1002/0471141755.ph13b05s53

Current Protocols in Pharmacology

Current Protocols in Pharmacology

How to Cite

Mo, H. 2011. In Vitro Anti-Hepatitis C Virus (HCV) Resistance Selection and Characterization. Current Protocols in Pharmacology. 53:B:13B.5:13B.5.1–13B.5.27.

Author Information

  1. Gilead Sciences, Inc., Foster City, California

Publication History

  1. Published Online: 1 JUN 2011
  2. Published Print: JUN 2011

Abstract

Understanding the resistance profile for an antiviral drug is essential in the drug discovery process. The selection of drug-resistant mutant viruses is critical in characterizing the resistance of hepatitis C virus (HCV) to anti-HCV agents, and can be examined in HCV replicon systems. Three basic methods are employed in this unit to select HCV resistance replicons: (i) cells containing HCV replicons are cultured at low density in the presence of G418 and a fixed concentration of the investigational drug; (ii) cells containing HCV replicons are passaged in the presence of a fixed concentration of investigational drug, but in the absence of G418; (iii) cells containing HCV replicons are passaged in the presence of a gradually increasing concentration of an investigational drug in the presence of G418 for several weeks. The cells from each passage are then harvested and stored for phenotypic and genotypic characterization. The protocols in this unit describe the techniques necessary to select and characterize drug- resistant HCV variants and estimate the frequency of drug resistance in a viral population. Curr. Protoc. Pharmacol. 53:13B.5.1-13B.5.27. © 2011 by John Wiley & Sons, Inc.

Keywords:

  • HCV;
  • resistance selection;
  • phenotype and genotype